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Copyright © 2009 AHC To clarify the significance of expression of system L amino acid transporter 1 (LAT1) and
4F2 heavy chain (4F2hc) in the developing intestine, immunohistochemical investigation and
molecular analysis were performed in the human embryonic and/or fetal intestines, ranging
from 28–30 days to 34–35 weeks gestation. The molecular analysis for the expression of
LAT1 and 4F2hc mRNAs was done in the pure epithelial cell samples prepared after laser
assisted microdissection. The immunoreactivities against LAT1 and 4F2hc were detected
along the basolateral cell membrane of the primitive gut epithelium at 28–30 days gestation.
According to advance in gestational age of up to 24–25 weeks gestation, the immunoreac-
tivity of LAT1 was predominantly observed in the supranuclear cytplasmic localization with
a granular or dot-like staining pattern. Up to 8–9 weeks gestation, the immunoreactivity of
4F2hc showed almost the same as that of LAT1. However, after the age of 12–13 weeks
gestation, the immunoreactivity of 4F2hc was predominantly localized along the cell mem-
brane of apical surface of the epithelial cells. No apical and linear membranous localization
of LAT1 was observed until nearly 20 weeks gestation. In the late gestational stage, both
the immunoreactivities against LAT1 and 4F2hc were localized along the apical surface of
the epithelial cells. In conclusion, the expression of LAT1 and 4F2hc in early developing in-
testine suggests they have a more important role in cell proliferation rather than functional
differentiation. The predominant cytoplasmic localization of LAT1 during mid-fetal life seems
to be largely inactive as amino acid transporter. On the other hand, the apical and linear
membranous co-localization of LAT1 and 4F2hc in the late fetal life suggests that these
molecules may play a role as a functional amino acid transporter in the fetal intestinal
epithelium.
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I. Introduction
It has been demonstrated that the uptake of amino acids
into the cells is essential to cell growth in both physiological
and neoplastic conditions [3, 11]. In addition to DNA and
protein synthesis, amino acid uptake is quite important to
cell differentiation [12, 24]. Amino acid uptake is mediated
by several types of amino acid transporters [3, 8]. System L
amino acid transporter 1 (LAT1), a Na+-independent amino
acid transporter, is a membrane protein with 12 putative
membrane-spanning domains and consisting of 512 amino
acids, that was originally cloned by Kanai et al. [10]. In adult
tissue, LAT1 expression is very low, except for brain, testisOhno et al. 74
and placenta [10, 25]. On the other hand, its expression is at
a relatively high level in tumor tissues and also in the tissues
showing high proliferating activity [9, 10, 15, 17], There-
fore, it has been suggested that LAT1 is one of the oncofetal
antigens [10, 25]. For its functional expression as an amino
acid transporter, LAT1 requires the presence of 4F2hc
(CD98), a heavy chain of the cell surface antigen, forming a
heterodimer (LAT1/4F2hc) on the cell membrane surface
[10]. The expression of LAT1 and LAT2 was examined
extensively in the different species including human and
also in the cell lines [2, 4, 5, 10, 14, 18–20, 25]. According
to previous studies using northern blotting, no expression of
LAT1 was demonstrated in adult human intestine [18, 25].
In addition, there is no systematic investigation of the ex-
pression of LAT1 and 4F2hc in human fetal intestine. In this
study, we examined the expression of LAT1 and 4F2hc pro-
teins and their mRNAs, and discuss the significance of their
expression in the human developing intestine.
II. Materials and Method
Human intestines
Twelve embryonic and/or fetal intestines, ranging from
the estimated gestational age of 28–30 days (Streeter’s hori-
zon XIV) to 34–35 weeks, were obtained from the surgical
specimens of spontaneous abortus and/or autopsy cases of
stillbirths and premature births under informed consent. All
the tissue samples were handled according to the Ethical
Guidelines for Clinical Studies (July 30, 2003, amended De-
cember 28, 2004, Ministry of Health, Labour and Welfare).
The intestines were fixed in 20% formalin, and embedded in
paraffin. Four micrometer thick sections were processed in
the usual manner, and stained with hematoxylin and eosin.
Immunohistochemistry for LAT1 and 4F2hc
Immunohistochemistry was done on formalin-fixed,
paraffin embedded tissue sections using labeled streptavidin
biotin; LSAB method (Histofine SAB-PO (R) kit, Nichirei
Biosciences Inc). Deparaffinized sections were quenched for
endogenous peroxidase activity by immersing the sections
into 0.3% hydrogen peroxide solution for 20 min at room
temperature, and washing several times in phosphate buffer
saline (PBS), pH 7.2. Prior to the incubation with primary
antibodies (rabbit anti-LAT1 and anti-4F2hc polyclonal, de-
scribed elsewhere) [25], the sections were incubated with
5% skimmed milk in PBS for blocking nonspecific binding.
The sections were then incubated with primary antibodies
for 1 hr at room temperature. After washing in PBS several
times, biotinylated anti-goat antibody was applied for 30
min at room temperature. After washing in the same way,
the tissue sections were incubated with horseradish peroxi-
dase (HRP) labeled streptavidin for 30 min at room tem-
perature. The tissue-bound HRP activity was visualized by
immersing the sections in 0.005% 3,3'-diaminobenzidine
tetrahydrochloride (DAB) in PBS containing hydrogen per-
oxide (10 µl/150 ml DAB solution). After the completion of
the immunohistochemical process, the sections were stained
lightly with hematoxylin, processed in the usual manner and
mounted.
Laser microdissection for tissue sections
Eight µm thick paraffin sections of the intestine were
mounted on membrane film-coated slide glasses. After
dewax with xylene, the sections were stained lightly with
toluidine blue, then the target cells were microdissected by
ultraviolet laser beam under a light microscope. For laser
microdissection, we used PALM MBIII-N (Zeiss). The
microdissected target cells were retrieved precisely into an
Eppendorf lid with mineral oil.
RNA extraction and reverse transcription
RAN extraction and reverse transcription were done in
accordance with our method described previously [16]. With
the microdissected cells mounted lids, the Eppendorf’s tubes
with 200 µl of denaturing buffer, containing 10 mM Tris-
HCl (pH 8.0), 25 mM EDTA (pH 8.0), 0.5% SDS and 100
mM NaCl and proteinase K were carefully covered and in-
cubated at 55°C overnight. Their total RNA was purified
with 20 µl 2M sodium acetate (pH 4.0), 220 µl citrate satu-
rated phenol (pH 4.3), and 60 µl chloroform-isoamyl alco-
hol. They were centrifuged for 15 min at 15,000 rpm and
transferred to the upper aqueous layer into a new tube. The
aqueous layer in the new tube was added to 200 µl isopro-
panol, 2 µl glycogen as a carrier and allowed to stand at
–80°C for more than 30 min. They were then recentrifuged
for 30 min at 14,000 rpm, and their supernatant was decant-
ed. The pellets were washed with 70% ethanol and air dried
on ice. They were then dissolved with 10 µl diethyl pyrocar-
bonate (DEPC) treated water, and store at –80°C until use.
To assess the concentration of the total RNA, one µl of it
was directly analyzed on a Nanodrop 1000 (Thermo Fisher
Scientific, Newark, DE, USA). The RNA extracted from the
microdissected cells was reverse transcribed in a final vol-
ume of 20 µl using a Quantitect reverse transcription kit
(QIAGEN, Tokyo, Japan) according to the manufacture’s
instructions.
Reverse transcriptase polymerase chain reaction (RT-PCR)
The quantity of LAT1 and 4F2hc mRNAs was meas-
ured by quantitative RT-PCR technique using the ABI
Prism 7000 Sequence Detection System (Applied Biosys-
tems Japan, Tokyo Japan). As an internal control, mRNA of
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was
measured. The RT-PCR primers used in this study are
shown in Table 1. The PCR amplification was performed
with a final volume of 20 µl of reaction mixture containing
900 µmol/l of each primer and 1×SYBR Green PCR Master
Mix (PE Applied Biosystems, Foster City, CA, USA). The
reaction was followed by 50 cycles at 95°C for 15 sec and
60°C for 1 min. The quantities of LAT1 and 4F2hc mRNAs
were standardized relative to the mRNA of GAPDH using
the standard curve method. The RT-PCR products were
electrophoresed through 2% agar gel and visualized with
SYBR Green I.LAT1/4F2hc in Human Developing Intesine 75
III. Results
Morphology of the primitive gut and fetal intestine
The primitive gut at the age of 28–30 days gestation
(Streeter’s horizon XIV) [21] is characterized by a simple
hollow tubular structure lined by stratified immature epithe-
lial cells and embedded in dense primitive mesenchymal
cells. No cellular differentiation is evident in the epithelial
cells (Fig. 1a). At the age of 34–36 days gestation (Streeter’s
horizon XVII) [22], the histology of the gut is still primitive,
and similar to that of 28–30 days gestation. However, the
subnuclear clear cytoplasm has become more obvious. On
the other hand, cellular differentiation can be seen in the
mesenchymal cells surrounding the primitive gut. The mes-
enchymal cells tend to encircle the primitive gut epithelial
cells, suggesting immature muscular differentiation (Fig. 2a,
b). At the age of 9–10 weeks gestation, cellular differentia-
tion is noted in the gut epithelial cells and the occurrence of
goblet cells is easily identified. After the age of 14–15 weeks
gestation, throughout the mid to late gestational stage (34–
36 weeks), the morphological appearance of the fetal intes-
tines is almost same, though the intestinal villi appear to be
lengthen and goblet cells are much more increased in num-
ber (Fig. 3a, 4a, 5a). In the late gestational stage (34–36
weeks), the formation of the brush border is obviously dem-
onstrated in the epithelial cells of intestinal villi (Fig. 5a).
Immunohistochemistry for LAT1 and 4F2hc
Both the LAT1 and 4F2hc immunoreactivities are dem-
onstrated in the primitive gut epithelial cells at the age of
28–30 days gestation. Rather weak but distinct immunoreac-
tivity of LAT1 was observed along the basolateral mem-
brane of epithelial cells (Fig. 1b). No immunoreactivity was
observed in the surrounding primitive mesenchymal cells.
At the age of 34–36 days gestation, more intense immuno-
reactivities against LAT1 and 4F2hc were observed in the
primitive gut epithelial cells, mainly along the basolateral
membrane (Fig. 2c, d). However, the immunoreactivity
against LAT1 is also observed in the cytoplasm, particularly
on the subnuclear basal side (Fig. 2c). An intense immuno-
reactivity against LAT1 was also observed in the primitive
muscle cells, vascular endothelial cells, immature chondro-
cytes, lining of embryonic coelomic cavity, generally cover-
ing the embryo or primitive epidermis (data not shown).
According to the advance of the intestinal development, at
the age of 15–16 weeks gestation, the immunoreactivities
against LAT1 and 4F2hc showed different localization pat-
terns. The immunoreactivity against LAT1 localized chiefly
in the cytoplasm, particularly in supranuclear localization
with a granular or dot-like staining pattern (Fig. 3b). On the
other hand, the immunoreactivity against 4F2hc predomi-
nantly showed an intense linear localization along the cell
membrane of the apical surface of the epithelial cells and
also in the cytoplasm (Fig. 3c). During the mid gestational
stage, the immunolocalization of LAT1 and 4F2hc was
nearly the same as those of 15–16 weeks gestation,
though the basolateral membranous staining was also ob-
served (Fig. 4b, c). In the late gestational stage (34–36
weeks), the immunoreactivities against LAT1 and 4F2hc
showed rather intense linear staining along the apical mem-
Table 1. RT-PCR primer sequences of LAT1 and 4F2hc, and product sizes
Target Forward primer Reverse primer
Annealing 
temperature 
(°C)
Product size 
(bp)
hLAT1 5'-CAT CCT GCT GGG CTT CGT-3' 5'-AGT TTG GTG CCT TCA AAT GAG AA-3' 60 81
h4F2hc 5'-CTC AGG CAA GGC TCC TGA CT-3' 5'-GGC AGG GTG AAG AGC ATC A-3' 60 76
GAPDH 5'-GAA GGT GAA GGT CGG AGT C-3' 5'-GAA GAT GGT GAT GGG ATT TC-3' 60 226
Fig. 1. Human developing intestine, 28–30 days gestation. Primitive gut, characterized by a hollow tubular structure made up of multilayered
immature epithelial cells, embedding in a dense mesenchymal background (a), H-E stain ×400 and a distinct basolateral membranous staining
of LAT1 (b), LSAB method, ×400.Ohno et al. 76
Fig. 2. Human developing intestine, 34–36 days gestation. Primitive gut, characterized by multilayered immature epithelial cells with clear sub-
nuclear appearance (a), (b), H-E stain ×200, ×400. Intense basolateral membranous staining of LAT1 (c) and 4F2hc (d), LASB method, ×400.
Fig. 3. Human developing intestine, 15–16 weeks gestation. Well developed intestinal villi with occasional goblet cells, H-E stain ×200 (a). Pre-
dominant cytoplasmic staining of LAT1 with a granular or dot-like pattern (b), and mainly linear staining of 4F2hc along the apical surface of
the epithelial cells (c), LASB method, ×400.LAT1/4F2hc in Human Developing Intesine 77
Fig. 4. Human developing intestine, 20–21 weeks gestation. Well developed and elongated intestinal villi with occasional goblet cells (a), H-E
stain ×200. Predominant cytoplasmic, but occasional membranous staining patterns of LAT1 (b), and chiefly membranous staining of 4F2hc
(c), LSAB method, ×400.
Fig. 5. Human developing intestine, 34–36 weeks gestation. Well developed intestinal villi with increased goblet cells and distinct brush borders
(a), H-E stain, ×400. Distinct membranous staining of LAT1 (b) and 4F2hc (c) in the intestinal villi along the apical surface, LSAB method,
×400.Ohno et al. 78
brane of the villous epithelial cells (Fig. 5b, c). Results
of the morphological development and immunohistochem-
ical expression of LAT1 and 4F2hc in human developing
intestines are summarized in Table 2.
Expression of LAT1 and 4F2h mRNAs in developing intestine 
by RT-PCR
In early developmental stage (Streeter’s horizon XIV,
28–30 days), the expression of LAT1 and 4F2hc mRNAs
was clearly observed in the cell sample obtained from the
primitive gut by laser microdissection. The PCR products of
4F2hc were constantly and intensely observed throughout
the developmental stages. On the other hand, the PCR prod-
ucts of LAT1 were usually barely observed compared with
those of 4F2hc. In some samples, the level of LAT1 mRNA
expression seemed to be below the range of detection
(Fig. 6).
IV. Discussion
To clarify the significance of expression of amino acid
transporter in the intestinal development and functional
differentiation, we investigated the expression of system L
amino acid transporter 1 (LAT1) and its cofactor 4F2
heavy chain (4F2hc) in the various stages of human devel-
oping intestines by immunohistochemistry and molecular
analysis using RT-PCR method. According to our previous
study, the development of intestinal villi and cellular
differentiation begins around at the age of 9–10 weeks ges-
tation [7]. Before this developmental stage (28–30 days to
34–36 days gestation), the primitive gut is characterized
by a straight hollow tubular structure, embedded in rather
dense undifferentiated mesenchymal cells. At this develop-
mental stage, of course, intestinal epithelial cells are also
immature and show marked stratification without any iden-
tifiable cellular differentiation. This histological appearance
is a hallmark of embryonic gut, and the stratification of
immature epithelial cells may reflect the marked prolif-
erating activity. In the embryonic gut epithelial cells, the
immunoreactivities against LAT1 and 4F2hc were satisfac-
torily demonstrated in the cell membrane, particularly along
the basolateral membrane. This finding seems to be quite
reasonable, because the immature epithelial cells uptake
nutrients and receive some growth signals from the basal
Table 2. Results of morphological development and immunohistochemical expression of LAT1 and 4F2hc in the human developing intestines
(–): not observed, (–/+): focal and incompletely developed, (+): occasionally observed, (2+): frequently observed. +: weakly positive, +/2+:
positive, 2+: intensely positive
Cases Gestational ages Morphology LAT1 4F2hc
1 28–30 days No villi or cellular differentiation +
basolateral, membranous
+
basolateral, membranous
2 34–36 days No villi or cellular differentiation 2+
basolateral, membranous
+
basolateral, membranous
3 44–46 days No villi or cellular differentiation 2+
basolateral, membranous
+
basolateral, membranous
4 8–9 weeks No villi or cellular differentiation 2+
basolateral, membranous
+
basolateral, membranous
5 9–10 weeks Villi (+), brush border (–/+), 
goblet cell (+)
2+
supra-/sub-nuclear, granular focally 
membranous
+
supra-/sub-nuclear, granular focally 
apical and linear
6 14–15 weeks Villi (+), brush border (–), 
goblet cell (+)
2+
predominantly supranuclear, granular 
focally subnuclear and membranous
2+
predominantly apical and linear, 
focally membranous
7 15–16 weeks Villi (+), brush border (–), 
goblet cell (2+)
2+
predominantly supranuclear and 
granular, occasionally subnuclear
+/2+
predominantly apical and linear, 
focally membranous
8 16–17 weeks Villi (+), brush border (–), 
goblet cell (2+)
2+
predominantly supranuclear and 
granular, occasionally subnuclear
+/2+
predominantly apical and linear, 
focally membranous
9 18–19 weeks Villi (+), brush border (–/+), 
goblet cell (2+)
2+
predominantly supranuclear and 
granular, occasionally subnuclear, 
focally apical and linear
2+
predominantly apical and linear, 
focally supranuclear and subnuclear
10 20–21 weeks Villi (+), brush border (–/+), 
goblet cell (2+)
2+
predominantly supranuclear and 
granular, occasionally subnuclear, 
focally apical and linear
2+
predominantly apical and linear, 
focally supranuclear and subnuclear
11 24–25 weeks Villi (+), brush border (+), 
goblet cell (2+)
2+
predominantly supranuclear and 
granular, occasionally subnuclear, 
focally apical and linear
+
supranuclear, and apical and linear
12 34–35 weeks Villi (+), brush border (2+), 
goblet cell (3+)
+/2+
apical and linear
+/2+
apical and linear, focally subnuclearLAT1/4F2hc in Human Developing Intesine 79
side via capillaries and/or paracrine modes.
LAT1 is an inducible type cell membrane protein,
which can be induced by physiologically activated sub-
stances such as hormones and growth factors, and the
expression of LAT1 is considered to be up-regulated in
association with the degree of cellular protein synthesis
requirement [3, 19, 20]. For example, in the process of
tissue regeneration, in other words, in the repairing process,
the up-regulated LAT1 expression has been demonstrated in
the cells of experimentally induced rat gastric ulcer edge
[13]. The up-regulated LAT1 expression at the ulcer edge
in the repairing process can be explained by the fact that
LAT1 enhances amino acid transport to both the mesen-
chymal cells in the granulation tissue, and epithelial cells in
the process of ulcer healing. On the other hand, in the neo-
plastic condition, tumor cells require increased amino acid
uptake for DNA and/or protein synthesis [6, 23]. The cells
contributing to the repairing or neoplastic condition require
increased uptake of amino acids for cell proliferation [1, 18].
In the early developmental stage, LAT1 and 4F2hc are
co-localized along the basolateral plasma membrane which
suggests the formation of LAT1/4F2hc heterodimer on the
cell surface. At this stage, the LAT1/4F2hc heterodimer
plays a role as a functional amino acid transporter contribut-
ing to the cell proliferation.
According to the advance of the gestational age, LAT1
is expressed predominantly in the cytoplasm, particularly as
supranuclear localization. This expression pattern of LAT1
continued throughout the end of mid-fetal life (24–25 weeks
gestation), and such cytoplasmic localization seems to be
functionally inactive. On the other hand, 4F2hc is expressed
constantly throughout the whole embryonic and/or fetal life.
During the mid to late fetal life, 4F2hc expressed predomi-
nantly membranous staining in the apical surface of the gut
epithelial cells. Such a discrepant localization of LAT1 and
4F2hc in the mid-fetal life suggests that 4F2hc may form a
heterodimer with other light chain, such as LAT2.
In this study, we did not confirm the subcellular
immunolocalization of LAT1 in the intestinal epithelial
cells. However, the granular or dot-like immunoreactivity
of LAT1 in supranuclear location may suggest that LAT1
exists as inappropriately folded and aggregated form at the
level of endoplasmic reticulum or Golgi apparatus during
the mid-fetal life. We do not have any reliable evidence for
the explanation of LAT1 localization changed from cyto-
plasmic to apical and linear pattern in the end of mid-fetal
to the late fetal life. Possible explanation of such apical and
linear expression of both LAT1and 4F2hc seems to be
physiological need, because the substrate of LAT1/4F2hc
comes form the ingested amniotic fluid at this stage. And
such a drastic change may be induced by time spatial acti-
vation of molecular chaperon of the transporter proteins.
RT-PCR examination showed rather intense and con-
stant expression of LAT2 mRNA in the gut epithelial cell
samples throughout the embryonic and/or fetal life (data not
shown). The constant and intense expression of 4F2hc
mRNA in the gut epithelial cells seems to be reasonable,
because 4F2hc expression has been demonstrated in almost
all cells.
Although the result of RT-PCR failed to visualize the
expression of LAT1 mRNA in some intestinal samples, we
obtained very low expression of LAT1 mRNA by the results
of relative to reference genes. The expression level of LAT1
mRNA showed roughly 1×10−3 and 1×10−3 lower than that of
LAT2 and 4F2hc, respectively (data not shown).
We observed co-localization of LAT1 and 4F2hc in the
epithelial cells of intestinal villi with a membranous and
linear staining pattern, at the late gestational stage (34–35
weeks gestation). Such a co-localization of LAT1 and 4F2hc
may play as a functional amino acid transporter at the intes-
Fig. 6. Expression of LAT1 and 4F2hc mRNAs in the human developing intestine. The PCR products of LAT1 and 4F2hc are both identified in
the early developing intestine (28–30 days gestation). The products of 4F2hc are constantly identified in the developing intestines throughout
the gestational stages. On the other hand, the products of LAT1 are usually barely observed. GAPDH: positive control. M: marker; (–): No
sample (negative control).Ohno et al. 80
tinal villi. It has been shown that intestinal epithelial cells
and renal tubular epithelial cells have developed original
transport system in the basolateral and luminal sides. There
is no report about the expression of LAT1/4F2hc in the fetal
intestine, and also in the adult ones. However, we thought
that the expression of functional amino acid transporter,
LAT1/4F2hc in the fetal intestine is possibly time-spatial. It
is necessary to investigate the expression of LAT1/4F2hc in
the intestine with circumstances of milk-feeding.
In this study, we disclosed that the expression of LAT1
and 4F2hc in the human embryonic and/or fetal intestines,
by immunohistochemistry and RT-PCR method. To our
knowledge, this is the first report to demonstrate the co-
expression of LAT1 and 4F2hc as an active molecule of
amino acid transporter in the human developing intestines.
In conclusion, the expression of LAT1 and 4F2hc in
early developing intestine suggests more important role in
cell proliferation rather than functional differentiation. The
predominant cytoplasmic localization of LAT1 during the
mid-fetal life seems to be largely inactive as amino acid
transporter. On the other hand, the apical and linear mem-
branous co-localization of LAT1 and 4F2hc in the late fetal
life suggests that these molecules may play as a functional
amino acid transporter in the fetal intestinal epithelium.
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